If we can detect it in urine, it's a biology-based condition.
For generations, the path to understanding a child's neurodevelopmental difference has run through observation, waiting, and uncertainty. Researchers at Arizona State University have now traced a new path through biology itself — a urine test measuring compounds produced by gut bacteria that, in early trials, identified autism in children with remarkable precision. The discovery does not merely offer a faster answer; it reframes autism, for many children, as a condition with a measurable biological signature, potentially easing the burden of diagnosis and opening doors to earlier, more targeted care.
- With 1 in 31 U.S. children affected by autism, families routinely endure months or years of behavioral observation and diagnostic queues before receiving answers — a delay that costs children critical early intervention time.
- A urine test measuring 17 gut-derived metabolites distinguished autistic children from typically developing peers with 90% sensitivity and 100% specificity, with some metabolites registering 100 to 1,000 times higher in autistic children.
- The elevated compounds are altered forms of serotonin and dopamine, offering a biological explanation for the social, emotional, and cognitive challenges many autistic children face — and prompting researchers to propose a new autism subtype, ASD-MDM.
- Early microbiota transplant therapy has already shown it can reduce one key problematic metabolite while improving both gut and behavioral symptoms, hinting at treatment pathways — though larger trials are needed before clinical adoption.
- The test is already being offered internationally through a UK partner laboratory, positioning it as a triage tool to move children to the front of evaluation queues and reduce the shame and hesitation some families feel in seeking diagnosis.
A child's urine may soon tell doctors what behavioral observation alone cannot. Researchers at Arizona State University have developed a screening tool that measures 17 compounds produced by gut bacteria, and in early trials it distinguished children with autism from typically developing peers with striking accuracy.
The test analyzes microbial metabolites in urine samples from children ages 2 to 11. Across a study of 52 autistic children and 47 typically developing peers, the pattern was unmistakable: nearly all autistic children had at least one metabolite far exceeding control levels — some 100 to 1,000 times higher. On average, autistic children had about three elevated metabolites; typically developing children had none. The test achieved 90 percent sensitivity and 100 percent specificity in the initial cohort.
Many of the compounds being measured are altered forms of serotonin and dopamine, offering a possible biological explanation for the social communication difficulties, anxiety, and attention challenges common in autism. The research, published in Molecular Psychiatry, proposes a new subtype — ASD-MDM — that may encompass roughly 90 percent of autism cases.
What makes this potentially transformative is the practical relief it could offer families. Current diagnosis depends on behavioral observation, and many parents endure long waits for evaluation. Christina Flynn, the study's first author and herself a parent of a child with autism, noted that a biology-based tool could reduce the hesitation some families feel about seeking diagnosis. The test is not meant to replace formal evaluation, but to move children to the front of the queue and guide earlier intervention — medical, behavioral, or educational.
The findings also hint at treatment possibilities. A preliminary clinical trial of microbiota transplant therapy found it substantially reduced one problematic metabolite, p-cresol sulfate, while improving both gut and behavioral symptoms. Larger trials are needed before such approaches can be widely recommended.
The test is already moving toward real-world availability through a UK partner laboratory. For a condition affecting an estimated 1 in 31 U.S. children — with lifetime care costs averaging 3.6 million dollars per person — even a modest narrowing of the diagnostic gap carries meaningful consequences for families and outcomes alike.
A child's urine might soon tell doctors what behavioral observation alone cannot: whether that child is at risk for autism. Researchers at Arizona State University have developed a screening tool that measures 17 compounds produced by gut bacteria, and in early trials, it distinguished children with autism from typically developing peers with striking accuracy.
The test works by analyzing microbial metabolites—small molecules created by microorganisms living in the digestive tract—in urine samples from children ages 2 to 11. When the team measured these compounds in 52 children diagnosed with autism spectrum disorder and 47 typically developing children across four states, the pattern was unmistakable. Nearly all the autistic children had at least one metabolite level far exceeding what researchers observed in the control group. Some measured 100 to 1,000 times higher. On average, children with autism had about three elevated metabolites; typically developing children had none. The test achieved 90 percent sensitivity—correctly identifying 90 percent of children with autism—and 100 percent specificity, meaning it did not misidentify any child without autism in the study.
The compounds being measured are not random. Many are altered versions of serotonin and dopamine, neurotransmitters that regulate mood, cognition, and memory. This biological finding offers a possible explanation for why so many autistic children experience social communication difficulties, anxiety, depression, and attention challenges. The research, published in Molecular Psychiatry, proposes a new autism subtype called ASD-MDM—autism spectrum disorder associated with microbially-derived metabolites—that encompasses roughly 90 percent of autism cases. The remaining 10 percent of children in the study who lacked abnormal gut metabolites typically had other significant metabolic problems possibly linked to genetic disorders.
What makes this development potentially transformative is not just the biology it reveals, but the practical relief it might offer families. Current autism diagnosis depends on behavioral observation, and many families endure long waits for evaluation and answers. Christina Flynn, the study's first author and a recent ASU PhD graduate who is herself a parent of a child with autism, emphasized that a biology-based screening tool could reduce the shame and hesitation some parents feel when seeking diagnosis. "If we can detect it in urine, it's a biology-based condition," she said. "Hopefully that will prevent any hesitancy on parents' parts to seek treatment and seek it as early as possible." The test is not meant to replace formal diagnosis, but rather to move children to the front of the evaluation queue and guide earlier intervention—whether medical, behavioral, or educational. Research consistently shows that earlier identification and treatment lead to better long-term outcomes.
The findings also hint at possible treatments. Some preliminary research suggests that microbiota-based therapies—interventions designed to restore a healthy gut microbiome—may reduce metabolite levels and improve symptoms. The team's first clinical trial of microbiota transplant therapy found that the treatment substantially decreased one problematic metabolite, p-cresol sulfate, while improving both gut symptoms and behavioral symptoms. But the researchers are cautious: much more rigorous testing is needed before such approaches can be widely recommended.
The test, called the Microbially-Derived Metabolite System, is already moving toward real-world availability. A partner laboratory in the United Kingdom is offering it internationally. For younger children, it could serve as a triage tool to identify who needs evaluation. For children already diagnosed, it might help clinicians understand the biological underpinnings of their condition and track how interventions affect their bodies over time.
The researchers acknowledge that larger, more diverse studies are needed to validate these findings and better understand how these metabolites relate to autism's development. But the potential stakes are substantial. Autism affects an estimated 1 in 31 children in the United States, with a lifetime care cost averaging 3.6 million dollars per person. For many families, the hardest part is the waiting—the uncertainty while seeking answers. If this test can narrow that gap, even modestly, it changes the calculus of early intervention and family burden. Flynn put it plainly: "If this test shortens that gap, even by a little, that's meaningful because earlier intervention can really help."
Notable Quotes
If this test shortens that gap, even by a little, that's meaningful because earlier intervention can really help.— Christina Flynn, study first author and parent of a child with autism
These are two key neurotransmitters that affect mood, cognition and memory. This could explain many of the symptoms and co-occurring symptoms in children with autism.— James Adams, corresponding author and researcher at ASU's Biodesign Center
The Hearth Conversation Another angle on the story
Why does a urine test matter more than what doctors already observe in a child's behavior?
Because behavior takes time to interpret, and families wait months or years for answers. A urine test is objective—it shows a biological pattern that exists whether or not a clinician is watching. It moves diagnosis from "we think we see something" to "we measured something."
But the test isn't a diagnosis by itself, right?
Correct. It's a screening tool. It tells you a child is at high risk and should move to the front of the evaluation line. The formal diagnosis still requires behavioral assessment. But now you're not starting from zero—you have biological evidence pointing the way.
What's the connection between gut bacteria and autism symptoms like social difficulty or anxiety?
The bacteria produce altered versions of serotonin and dopamine. Those are the brain's chemical messengers for mood, cognition, memory. If a child's gut is producing too much of these altered compounds, it could be flooding their system with something that looks like the real thing but isn't quite right. That could affect how their brain processes social information or manages anxiety.
Is this saying gut bacteria cause autism?
No. The research shows these metabolites are strongly associated with autism in most cases, but association isn't causation. About 10 percent of autistic children in the study didn't have abnormal metabolites at all. Autism is complex. This test captures one biological pathway that seems to matter for many children, not all.
What changes if parents know about this test?
Everything, potentially. Right now, parents sometimes delay seeking diagnosis because they feel shame—like they're failing as parents. If you can show them it's a measurable biological condition, not a parenting failure, more families seek help earlier. And earlier help genuinely improves outcomes.
What happens next?
More studies with larger, more diverse groups. Clinical trials of microbiota therapies to see if reducing these metabolites actually improves symptoms. And the test itself needs to be validated more broadly before it becomes standard screening. But it's already available internationally, so the real-world testing is beginning now.